Qualigen Therapeutics Shareholders Vote for a Revolutionary Change
In a bold move, Qualigen Therapeutics' stockholders have voted for a complete rebranding and strategic shift, with a new name and vision. But here's the twist: the company is entering the world of AI and Web3, leaving its biotechnology roots behind.
- Shareholders have given the green light to Faraday Future Intelligent Electric Inc. ("Faraday Future") to become the new majority shareholder, with a significant 55% direct equity ownership, rising to 63% when including affiliated shareholders.
- Faraday Future will play a crucial role in the upcoming board restructuring, which will be finalized before the company's public rebranding ceremony on November 20, 2025.
- On the same day, the company will officially become AIxCrypto Holdings, Inc. (Nasdaq: AIXC) and unveil its new identity at Nasdaq Headquarters in New York. This ceremony will be a pivotal moment, revealing a new business model, ecosystem, and a three-year roadmap to dominate the AI × Web3 space.
And this is where it gets exciting: the transformation aims to create a synergistic relationship between AIxCrypto and Faraday Future, boosting innovation and long-term growth.
The rebranding signifies a comprehensive overhaul, impacting the company's identity, business model, technology strategy, and ecosystem positioning. It's a definitive shift towards a decentralized AI (DeAI) and Web3-centric approach, marking a new era for the company.
Unveiling a New Strategic Vision
During the November 20 ceremony, the company will share its ambitious plans, including a new business framework and a three-year development strategy. Jerry Wang, Co-CEO of Qualigen Therapeutics, emphasizes that this is more than a name change; it's a complete evolution of the company's identity and global positioning.
The approved proposals include:
- Issuing common and convertible preferred shares under Nasdaq rules.
- Exceeding Nasdaq's issuance threshold.
- Implementing a 2025 Equity Incentive Plan to retain talent and align with shareholder interests.
- The ability to adjourn the meeting for additional voting matters if necessary.
With these approvals, the company is set to execute its new strategy as AIxCrypto.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics is a Carlsbad, California-based biotechnology company, focusing on oncology and immunology therapies. They are now expanding into crypto assets and Web3, merging technology with capital market innovation for global growth.
Disclaimer: This release contains forward-looking statements, which are subject to risks and uncertainties. The company's actual results may differ, and they caution against placing undue reliance on these statements.
For more information, contact the Investor Relations Department at Qualigen Therapeutics, Inc.
